JP Morgan Cuts SHC to Underweight as Short Interest Jumps 21%

Sotera Health enters earnings season with a fresh downgrade from a bellwether bank landing the same week that short sellers added meaningfully to positions, creating an unusually charged backdrop ahead of the November 4 print.

The most immediate news is the JP Morgan move. Casey Woodring downgraded the stock to Underweight from Neutral this morning, setting a $17 target, below the current price of $18.21. That puts the stock's largest near-term risk squarely in the valuation frame: the bear case cites a reduction to 12x EV/EBITDA on forward estimates and notes that peer-group multiple compression is weakening the sector's price support. The current EV/EBITDA multiple runs at 10.6x, already below the level the bear case implies, so the debate is less about the multiple itself and more about whether EBITDA estimates hold. Bulls counter with solid Q2 execution: Sterigenics delivered $212 million in revenue, up 7% in constant currency, adjusted EBITDA margins came in at 51.6%, and management raised full-year constant-currency guidance to 5.25% to 6.75% revenue growth. The consensus remains a hold, with one hold and one underperform rated, and a mean target of $22.61. Several firms that lifted targets aggressively after the August print, including Citigroup to $25 and Piper Sandler to $25, remain on the buy side; those notes are now two months old and predate the JP Morgan action.

Short positioning is building in a way that makes the downgrade harder to dismiss. Short interest climbed 21% in the past week to 5.2% of the free float, and is up nearly 25% over the past month. The acceleration is sharp: shares short held relatively flat through most of September, then jumped by roughly 2.3 million shares between October 7 and October 8, the single largest one-week step-up in the trailing 30-day window. Despite this, the borrow market remains far from stressed. Cost to borrow is 0.33%, essentially unchanged and historically low. Availability is extremely loose at 1,889%, meaning there are roughly nineteen shares available to borrow for every one already lent out. That is well off the 52-week tightest reading of 506%. In practical terms, shorts face no friction adding further. The setup is one of growing conviction rather than a squeeze dynamic.

Options positioning offers little drama by comparison. The put/call ratio is 0.011, below its 20-day average of 0.014, and the z-score is mildly negative at -0.43. Calls vastly outnumber puts, though the absolute PCR level is so low that the signal is ambiguous rather than clearly bullish. The 52-week range for the PCR runs from 0.0007 to 6.48, so this week's reading is well toward the call-heavy end but not at an extreme. Options traders are not piling into downside protection ahead of the earnings event.

The ownership picture adds texture. Sessa Capital holds 9.5% and Darsana Capital 9.5% on a last-reported basis, both passive 13G filers. Sculptor Capital, at 8.4%, added 2.3 million shares in the most recent period. BlackRock increased its stake to 8.4% as of September 30, adding 3.3 million shares. FMR (Fidelity) is also notable: a reported position of 6.2 million shares with a last-change figure of 6.1 million shares, suggesting a near-complete new build. Warburg Pincus and GTCR, both former private equity owners, exited their remaining stakes by May 2026, and Sachem Head Capital reduced below the 5% disclosure threshold as of October 9, filing a 13G/A showing zero shares. That exit by Sachem Head is the most notable recent flow on the register. All 13D/G stakes are as last disclosed and holders dropping below 5% may not file again.

On the insider front, the signal from the open-market register is sellers-only in the past 90 days. Executive Chairman Michael Petras sold 1.14 million shares at $18.50 in mid-August for total proceeds of roughly $21 million, with no 10b5-1 plan declared. The President of Sterigenics sold 150,000 shares the same week. Net open-market activity over 90 days is negative 1.3 million shares. Compensation grants to the CEO and directors in May are excluded from that count, as awards carry no directional signal on conviction.

With the next earnings release scheduled for November 4, the focus in the coming weeks will be on whether the JP Morgan downgrade pulls additional analyst opinion toward the cautious end, how the short position behaves as the event approaches, and whether the management guidance upgrade from August survives contact with Q3 results.